Q-omics provides the consensus-scored LINC01018 profile across patient tissues and cancer cell-line models. LINC01018 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01018 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01018 RNA expression shows 16,976 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where LINC01018 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01018 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01018 survival associations across molecular data types. LINC01018 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01018 RNA expression–survival associations across cancer types. High LINC01018 expression shows unfavorable associations in BLCA, UCEC and DLBC, but favorable associations in ACC, LIHC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01018 RNA expression.
This table summarizes LINC01018 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01018. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01018 shows lower tumor expression in KIRC, LIHC, KIRP, STAD, COAD and UCEC. The KIRC box plot shows higher LINC01018 RNA expression in normal versus tumor tissue (log2 FC = −1.683, t-test p < 0.001).
This table shows molecular features associated with LINC01018 in patient tissues and cancer cell lines. In patient samples, LINC01018 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
